

DYNAMICS OF SERUM LEVELS OF LEPTIN, MODULATOR OF GROWTH TGF- 1 AND PRO-INFLAMMATORY CYTOKINE IL-1 IN THE SYSTEMIC CIRCULATION IN PATIENTS WITH PSORIASIS AND OVERWEIGHT UNDER THE INFLUENCE OF SYSTEMIC OBESITY TREATMENT

Al Kasem Amin

SUMMARY

In patients with cutaneous forms of psoriasis with obesity and hyperleptinemia the dynamics of cytokines TGF- 1 and IL-1 under the influence of systemic treatment of obesity with the use of acarbose (Glyukobay) were studied. It is established that added of acarbose (glyukobay) to complex treatment of psoriasis can significantly reduce hyperleptinemia and the level of pro-inflammatory cytokine IL-1 . There were no significant effect of acarbose treatment (Glyukobay) at the level of the active form of TGF- 1 in patients with psoriasis.

IL-1

TGF- 1

TGF- 1 IL-1

()

TGF- 1

() IL-1

()

:

1

[6, 12, 14].

, 2006),

IL-1 , IL-6, IL-8, TNF- [1, 7].

[16].

[8].

(2006)

TGF- β 1 IL-1
 32 (BMI) < 25,0, 2- 3- 500-600 [18, 20].
 -32 34 , BMI \geq 30,0.
 «Leptin (human) EIA Kit» (Cayman Chemical Company, IL-1 1- , 2- 3- .1. (.1), « » (). TGF- β 1 «TGF- β 1 E_{max}[®] ImmunoAssay System» (Promega,). 27,6% (< 0,001), 121,4% 125,8% (< 0,001). (), BMI) - [5, 19]; 2- 3- 38,1% (₁ < 0,001). () Th1- 12- () 150 / . IL-1 , IL-6, TNF- IL-12 [11]. 150 300 [2]. [5]. (()), IL-1 () 50 1 , 2- .IL-1 [13]. IL-1 -50 2 () 3- [13]. IL-1 50 3 2- 3- [3]. IL-1 (,) [13].

1

1- , 2- 3-

TGF- 1

IL-1

Группы	Стат. показ.	Уровень лептина		IL-1 β		TGF- β 1	
		При поступлении	После лечения	При поступлении	После лечения	При поступлении	После лечения
1-я группа	M \pm m	7834,52 \pm	7753,12 \pm	46,13 \pm 1,24	43,00 \pm	376,30 \pm 12,08	363,03 \pm 14,30
	n	91,35	83,10	32	1,25	32	30
	p	32	30	< 0,001	30	< 0,001	< 0,001
	p ₁	< 0,001	< 0,001	–	< 0,05	–	< 0,001
2-я группа	M \pm m	13591,86 \pm	13814,09 \pm	64,18 \pm 1,30	58,60 \pm	416,30 \pm 16,46	348,15 \pm 11,41
	n	127,94	\pm 112,31	32	1,29	32	29
	p	32	29	< 0,001	29	< 0,001	< 0,001
	p ₁	< 0,001	< 0,001	–	< 0,001	–	< 0,001
3-я группа	M \pm m	13862,07 \pm	8575,45	62,24 \pm 1,32	43,73 \pm	422,14 \pm 15,50	343,29 \pm 13,31
	n	119,47	\pm 94,83	34	1,19	34	31
	p	34	31	< 0,001	31	< 0,001	< 0,001
	p ₁	< 0,001	< 0,001	–	< 0,02	–	< 0,001
Здоровые лица	M \pm m	6138,31 \pm	89,80	39,07 \pm 1,55	< 0,001	276,14 \pm 6,87	
	n	28	28	28	< 0,001	28	
	p	–	< 0,001	< 0,001	< 0,001	> 0,5	< 0,5
	p ₂	< 0,001	< 0,001	< 0,001	< 0,001		

IL-1

IL-1- IL-1- , TGF-

IL-1 IL-1

IL-1 [17]. IL-1 6 6 TGF- TGF-

6 IL-1,)

6 IL-1 (), [15].

TGF- 1 (1- ,2- 3-)

[9].

IL-1 [10]. IL-1 ()

1- 16,4%, ₁<0,001 2- 3- (18,7%, ₁<0,001),

18,1% (<0,001), 2- 3- 64,3% 59,3% (<0,001),

1- (1.

1- 2- ,1- 3- <0,001). IL-1 , TGF- 1.

IL-1 1- 2- 3- 8,7% (₁<0,01) 29,7% (₁<0,01).

2. ()

-IL-1 - IL-1 . ()

TGF- TGF- 1

1. CD14 CD19+-

IL-1 [4]. (TGF- , / . // . -2007.- .10, 4.- .31-33.

TGF-); () 2. . . . /

TNF- IL-1 1999.-343 . 3. . . . -1, -6 (

[4]. TGF-)/ . . // -2003.-

T.12.-C.3-10. 4. : / ,

5. « » ()/ . . , . . // . . . - 2005. - 1(3). - . 13-21.
6. Anti-tumor necrosis factor- blockade improves insulin resistance in patients with rheumatoid arthritis / M. Gonzalez-Gay, J. De Matias, C. Gonzalez-Juanatey [et al.] // Clin. Exp. Rheumatol. - 2006. - Vol. 24. - P. 83 - 86.
7. Bonifati C. Cytokines in psoriasis / C. Bonifati, F. Ameglio // Int. J. Dermatol. - 1999. - Vol. 38. - P. 241 - 251.
8. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study / L. Naldi, L. Chatenoud, D. Linder [et al.] // J. Invest. Dermatol. - 2005. - Vol. 125. - P. 61 - 67.
9. Interleukin-1 induces transcription of keratin K6 in human epidermal keratinocytes / M. Komine, L.S. Rao, I.M. Freedberg [et al.] // J. Invest. Dermatol. - 2001. - Vol. 116, N. 2. - P. 330 - 338.
10. Kanda N. Leptin enhances human beta-defensin-2 production in human keratinocytes / N. Kanda, S. Watanabe // Endocrinology. - 2008. - Vol. 149, N. 10. - P. 5189 - 5198.
11. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? / F. Caldefie-Chezet, A. Poulin, A. Tridon [et al.] // J. Leukocyte Biol. - 2001. - Vol. 69. - P. 414 - 418.
12. Metabolic and vascular effects of tumor necrosis factor- blockade with etanercept in obese patients with type 2 diabetes / H. Dominguez, H. Storgaard, C. Rask-Madsen [et al.] // J. Vasc. Res. - 2005. - Vol. 42. - P. 517 - 525.
13. Patel R.V. Psoriasis / R.V. Patel, M. Lebwohl // Ann. Intern. Med. - 2011. - Vol. 155, N. 3. - P. 21.
14. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab / C. Gonzalez-Juanatey, J. Llorca, A. Sanchez-Andrade [et al.] // Clin. Exp. Rheumatol. - 2006. - Vol. 24. - P. 309 - 312.
15. Sporn M.B. The early history of TGF-beta, and a brief glimpse of its future / Sporn M.B. // Cytok. Growth Fact. Rev. - 2006. - Vol. 17, N. 1-2. - P. 3 - 7.
16. Sterry W. International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications: report of an interdisciplinary conference and review / W. Sterry, B.E. Strober, A. Menter // Br. J. Dermatol. - 2007. - Vol. 157, N. 4. - P. 649 - 655.
17. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis / R. Debets, J.P. Hegmans, P. Croughs [et al.] // J. Immunol. - 1997. - Vol. 158, N. 6. - P. 2955 - 2963.
18. Waxman A. WHO global strategy on diet, physical activity and health / Waxman A., World Health Assembly // Food Nutr. Bull. - 2004. - Vol. 25, N. 3. - P. 292 - 302.
19. Willms B. Comparison of acarbose and metformin in patient with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study / B. Willms, D. Ruge // Diab. Med. - 1999. - Vol. 16. - P. 755 - 761.
20. World Health Organisation. Diet, nutrition and the prevention chronic disease // Report of a Joint/FAO Expert Consultation. Geneva. WHO. - 2003. - P. 149.